We have recently developed p62 (SQSTM1)-encoding plasmid (DNA vaccine) which demonstrated anti-cancer activity in animals models [13–15] and in the phase I/IIa clinical trial in patients with solid tumors [16]. This evidence concerns the gene SQSTM1 and cancer.